Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 1
1954 1
1955 2
1957 4
1958 4
1959 1
1960 2
1961 4
1962 6
1963 2
1964 3
1965 4
1966 3
1967 4
1968 11
1969 12
1970 14
1971 14
1972 6
1973 3
1974 6
1975 4
1976 5
1977 8
1978 10
1979 21
1980 12
1981 18
1982 27
1983 26
1984 33
1985 23
1986 24
1987 31
1988 35
1989 31
1990 31
1991 25
1992 27
1993 27
1994 29
1995 28
1996 34
1997 27
1998 36
1999 24
2000 33
2001 29
2002 23
2003 30
2004 30
2005 36
2006 40
2007 31
2008 28
2009 34
2010 59
2011 32
2012 50
2013 46
2014 44
2015 58
2016 49
2017 62
2018 48
2019 55
2020 63
2021 40
Text availability
Article attribute
Article type
Publication date

Search Results

1,521 results
Results by year
Filters applied: . Clear all
Page 1
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Hida T, et al. Among authors: yoshioka h. Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10. Lancet. 2017. PMID: 28501140 Clinical Trial.
Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer.
Watanabe SI, Nakagawa K, Suzuki K, Takamochi K, Ito H, Okami J, Aokage K, Saji H, Yoshioka H, Zenke Y, Aoki T, Tsutani Y, Okada M; Lung Cancer Surgical Study Group (LCSSG) of the Japan Clinical Oncology Group (JCOG). Watanabe SI, et al. Among authors: yoshioka h. Jpn J Clin Oncol. 2017 Dec 1;47(12):1112-1118. doi: 10.1093/jjco/hyx147. Jpn J Clin Oncol. 2017. PMID: 29136212 Review.
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, Nishio M, Kaneda H, Takayama K, Ishimoto O, Takeda K, Yoshioka H, Tachihara M, Sakai H, Goto K, Yamamoto N. Takahashi T, et al. Among authors: yoshioka h. Lancet Oncol. 2017 May;18(5):663-671. doi: 10.1016/S1470-2045(17)30230-9. Epub 2017 Mar 23. Lancet Oncol. 2017. PMID: 28343976 Clinical Trial.
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Nakagawa K, Hida T, Nokihara H, Morise M, Azuma K, Kim YH, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Koyama R, Mitsudomi T, Yamamoto N, Asakawa T, Hayashi M, Hasegawa W, Tamura T. Nakagawa K, et al. Among authors: yoshioka h. Lung Cancer. 2020 Jan;139:195-199. doi: 10.1016/j.lungcan.2019.11.025. Epub 2019 Nov 28. Lung Cancer. 2020. PMID: 31812890
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.
Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N. Akamatsu H, et al. Among authors: yoshioka h. Int J Clin Oncol. 2019 Jul;24(7):731-770. doi: 10.1007/s10147-019-01431-z. Epub 2019 May 2. Int J Clin Oncol. 2019. PMID: 31049758 Free PMC article.
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group. Mitsudomi T, et al. Among authors: yoshioka h. Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18. Lancet Oncol. 2010. PMID: 20022809 Clinical Trial.
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer.
Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T. Yoshioka H, et al. Ann Oncol. 2019 Dec 1;30(12):1978-1984. doi: 10.1093/annonc/mdz399. Ann Oncol. 2019. PMID: 31553438 Free article. Clinical Trial.
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K. Haratani K, et al. Among authors: yoshioka h. Ann Oncol. 2017 Jul 1;28(7):1532-1539. doi: 10.1093/annonc/mdx183. Ann Oncol. 2017. PMID: 28407039 Free article.
1,521 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page